NCT04471727 2026-02-24MK-6070-001Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 Active not recruiting232 enrolled
NCT05000294 2026-02-18Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesUniversity of FloridaPhase 1/2 Suspended29 enrolled
NCT06943521 2025-12-11A Study of MT-4561 in Patients With Various Advanced Solid TumorsTanabe Pharma America, Inc.Phase 1/2 Recruiting27 enrolled
NCT03647163 2025-09-16Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsVyriad, Inc.Phase 1/2 Active not recruiting33 enrolled